Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5124)
All Articles published online
|
Dec 7, 2012 (publication date) through Dec 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhao ZK, Yu HF, Wang DR, Dong P, Chen L, Wu WG, Ding WJ, Liu YB. Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World J Gastroenterol 2012; 18(45): 6651-6656 [PMID: 23236241 DOI: 10.3748/wjg.v18.i45.6651] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i45/6651.htm |
| Number | Citing Articles |
| 1 |
Fan Liu, Lan Wang, Fabiana Perna, Stephen D. Nimer. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nature Reviews Cancer 2016; 16(6): 359 doi: 10.1038/nrc.2016.41
|
| 2 |
Hong-Min Liu, Feng-Zhi Suo, Xiao-Bo Li, Ying-Hua You, Chun-Tao Lv, Chen-Xing Zheng, Guo-Chen Zhang, Yue-Jiao Liu, Wen-Ting Kang, Yi-Chao Zheng, Hai-Wei Xu. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors. European Journal of Medicinal Chemistry 2019; 175: 357 doi: 10.1016/j.ejmech.2019.04.065
|
| 3 |
Ting Ma, Anqi Li, Yueyang Guo, Shaotong Li, Meng Li, Siqi Feng, Hongmin Liu. KDM1A/LSD1 as a promising target in various diseases treatment by regulating autophagy network. Biomedicine & Pharmacotherapy 2022; 148: 112762 doi: 10.1016/j.biopha.2022.112762
|
| 4 |
Jiaxin Zhang, Leaf Huang, Guangbo Ge, Kaili Hu. Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment. Advanced Science 2023; 10(7) doi: 10.1002/advs.202206169
|
| 5 |
Jun Yu Tay, Josh Xingchong Ho, Fan Foon Cheo, Jabed Iqbal. The Tumour Microenvironment and Epigenetic Regulation in BRCA1 Pathogenic Variant-Associated Breast Cancers. Cancers 2024; 16(23): 3910 doi: 10.3390/cancers16233910
|
| 6 |
Yan Li, Xin Tian, Cheng-Guang Sui, You-Hong Jiang, Yun-Peng Liu, Fan-Dong Meng. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells. Biomedicine & Pharmacotherapy 2016; 82: 498 doi: 10.1016/j.biopha.2016.04.070
|
| 7 |
Lea M. Stitzlein, Jack T. Adams, Erin N. Stitzlein, Richard W. Dudley, Joya Chandra. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks. Journal of Experimental & Clinical Cancer Research 2024; 43(1) doi: 10.1186/s13046-023-02923-7
|
| 8 |
Jea-Woon Ryu, Seon-Kyu Kim, Mi-Young Son, Su-Jin Jeon, Jung-Hwa Oh, Jung Hwa Lim, Sunwha Cho, Cho-Rok Jung, Ryuji Hamamoto, Dae-Soo Kim, Hyun-Soo Cho. Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget 2017; 8(70): 115444 doi: 10.18632/oncotarget.23296
|
| 9 |
Federico Pedicona, Pedro Casado, Maruan Hijazi, John G. Gribben, Kevin Rouault-Pierre, Pedro R. Cutillas. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. Science Signaling 2022; 15(730) doi: 10.1126/scisignal.abl7989
|
| 10 |
Wen Fong Ooi, Xiaosai Yao, Patrick Tan, Bin Tean Teh. DNA and Histone Methylation as Cancer Targets. Cancer Drug Discovery and Development 2017; : 221 doi: 10.1007/978-3-319-59786-7_8
|
| 11 |
Chen Zhou, Di Kang, Yungen Xu, Luyong Zhang, Xiaoming Zha. Identification of Novel Selective Lysine‐Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore‐Based Virtual Screening Combined with Docking. Chemical Biology & Drug Design 2015; 85(6): 659 doi: 10.1111/cbdd.12461
|
| 12 |
Hao-Ran Sun, Shun Wang, Shi-Can Yan, Yu Zhang, Peter J. Nelson, Hu-Liang Jia, Lun-Xiu Qin, Qiong-Zhu Dong. Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.01104
|
| 13 |
Aditi Bhattacharya. Epigenetics in Organ Specific Disorders. 2023; : 497 doi: 10.1016/B978-0-12-823931-5.00005-0
|
| 14 |
Satoi Nagasawa, Anna S. Sedukhina, Yuko Nakagawa, Ichiro Maeda, Manabu Kubota, Shigeko Ohnuma, Koichiro Tsugawa, Tomohiko Ohta, Marta Roche-Molina, Juan A. Bernal, Ana J. Narváez, Anand D. Jeyasekharan, Ko Sato, Jindan Yu. LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLOS ONE 2015; 10(2): e0118002 doi: 10.1371/journal.pone.0118002
|
| 15 |
Xiaoming Zha, Liming Wu, Siyuan Xu, Fangxia Zou, Jiayue Xi, Tianfang Ma, Rongfeng Liu, Yu-Chih Liu, Dawei Deng, Yueqing Gu, Jinpei Zhou, Fei Lan. Design, synthesis and biological activity of N-(3-substituted-phenyl)benzenesulfonamides as selective and reversible LSD1 inhibitors. Medicinal Chemistry Research 2016; 25(12): 2822 doi: 10.1007/s00044-016-1706-8
|
| 16 |
Qilian Yang, Yuqing Yang, Nianxin Zhou, Kexin Tang, Wayne Bond Lau, Bonnie Lau, Wei Wang, Lian Xu, Zhengnan Yang, Shuang Huang, Xin Wang, Tao Yi, Xia Zhao, Yuquan Wei, Hongjing Wang, Linjie Zhao, Shengtao Zhou. Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer 2018; 17(1) doi: 10.1186/s12943-018-0855-4
|
| 17 |
Sangchul Kim, Amina Bolatkan, Syuzo Kaneko, Noriko Ikawa, Ken Asada, Masaaki Komatsu, Shinya Hayami, Hidenori Ojima, Nobutsugu Abe, Hiroki Yamaue, Ryuji Hamamoto. Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma. Biomolecules 2019; 9(12): 810 doi: 10.3390/biom9120810
|
| 18 |
Emily R. Theisen, Julia Selich-Anderson, Kyle R. Miller, Jason M. Tanner, Cenny Taslim, Kathleen I. Pishas, Sunil Sharma, Stephen L. Lessnick. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics 2021; 16(4): 405 doi: 10.1080/15592294.2020.1805678
|
| 19 |
Genbao Shao, Jie Wang, Yuanxia Li, Xiuwen Liu, Xiaodong Xie, Xiaolei Wan, Meina Yan, Jie Jin, Qiong Lin, Haitao Zhu, Liuping Zhang, Aihua Gong, Qixiang Shao, Chaoyang Wu. Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. Scientific Reports 2015; 5(1) doi: 10.1038/srep15344
|
| 20 |
Chao Han, Shanshan Wang, Zhongrui Li, Chen Chen, Jiqin Hou, Dingqiao Xu, Ruizhi Wang, Yaolan Lin, Jianguang Luo, Lingyi Kong. Bioactivity-guided cut countercurrent chromatography for isolation of lysine-specific demethylase 1 inhibitors from Scutellaria baicalensis Georgi. Analytica Chimica Acta 2018; 1016: 59 doi: 10.1016/j.aca.2018.01.014
|
| 21 |
Georgia Papadopoulou, Stavroula Petroulia, Eirini Karamichali, Alexios Dimitriadis, Dimitrios Marousis, Elisavet Ioannidou, Panagiota Papazafiri, John Koskinas, Pelagia Foka, Urania Georgopoulou. The Epigenetic Controller Lysine-Specific Demethylase 1 (LSD1) Regulates the Outcome of Hepatitis C Viral Infection. Cells 2023; 12(21): 2568 doi: 10.3390/cells12212568
|
| 22 |
Bin Peng, Jing Wang, Yuan Hu, Hongli Zhao, Wenya Hou, Hongchang Zhao, Hailong Wang, Ji Liao, Xingzhi Xu. Modulation of LSD1 phosphorylation by CK2/WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage. Nucleic Acids Research 2015; 43(12): 5936 doi: 10.1093/nar/gkv528
|
| 23 |
Suemi Yabuta, Yoshihiro Shidoji.
Cytoplasmic translocation of nuclear LSD1 (
KDM1A
) in human hepatoma cells is induced by its inhibitors
. Hepatic Oncology 2019; 6(2) doi: 10.2217/hep-2018-0008
|
| 24 |
Maite G. Fernández-Barrena, María Arechederra, Leticia Colyn, Carmen Berasain, Matias A. Avila. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Reports 2020; 2(6): 100167 doi: 10.1016/j.jhepr.2020.100167
|
| 25 |
Cong Chen, Jing Ge, Qibin Lu, Guoqiang Ping, Chunqing Yang, Xuefeng Fang. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer. Journal of Ovarian Research 2015; 8(1) doi: 10.1186/s13048-015-0155-1
|
| 26 |
Yixiang Sun, Ruicheng Lv, Tianxiao Wu, Xiangyu Zhang, Yin Sun, Jiangkun Yan, Ziheng Zhang, Dongmei Zhao, Maosheng Cheng. Design, synthesis, and biological evaluation of coumarin analogs as novel LSD1 inhibitors. Archiv der Pharmazie 2022; 355(2) doi: 10.1002/ardp.202100311
|
| 27 |
Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkataswamy Sorna, Mary C. Beckerle, Sunil Sharma, Stephen L. Lessnick. Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth. Clinical Cancer Research 2014; 20(17): 4584 doi: 10.1158/1078-0432.CCR-14-0072
|
| 28 |
Isamu Hoshino, Masahiko Takahashi, Yasunori Akutsu, Kentaro Murakami, Yasunori Matsumoto, Hiroshi Suito, Nobufumi Sekino, Aki Komatsu, Keiko Iida, Takayoshi Suzuki, Itsuro Inoue, Fumitaka Ishige, Yosuke Iwatate, Hisahiro Matsubara. Genome‑wide ChIP‑seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells. Oncology Letters 2019; doi: 10.3892/ol.2019.10350
|
| 29 |
Yuan Liu, Yanan Wang, Chunqin Chen, Jiawen Zhang, Wenyan Qian, Yu Dong, Zhiqiang Liu, Xi Zhang, Xiaoyun Wang, Zhenbo Zhang, Xiaobing Shi, Sufang Wu. LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter. Oncotarget 2017; 8(7): 11329 doi: 10.18632/oncotarget.13516
|
| 30 |
Juan Bayo, Esteban J. Fiore, Luciana M. Dominguez, Alejandrina Real, Mariana Malvicini, Manglio Rizzo, Catalina Atorrasagasti, Mariana G. García, Josepmaria Argemi, Elisabeth D. Martinez, Guillermo D. Mazzolini. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. Journal of Hepatology 2019; 71(1): 78 doi: 10.1016/j.jhep.2019.03.007
|
| 31 |
Monica Cusan, Sheng F. Cai, Helai P. Mohammad, Andrei Krivtsov, Alan Chramiec, Evangelia Loizou, Matthew D. Witkin, Kimberly N. Smitheman, Daniel G. Tenen, Min Ye, Britta Will, Ulrich Steidl, Ryan G. Kruger, Ross L. Levine, Hugh Y. Rienhoff, Richard P. Koche, Scott A. Armstrong. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood 2018; 131(15): 1730 doi: 10.1182/blood-2017-09-807024
|
| 32 |
G R Sareddy, S Viswanadhapalli, P Surapaneni, T Suzuki, A Brenner, R K Vadlamudi. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway. Oncogene 2017; 36(17): 2423 doi: 10.1038/onc.2016.395
|
| 33 |
Mehdi Bouhaddou, Li J. Yu, Serena Lunardi, Spyros K. Stamatelos, Fiona Mack, James M. Gallo, Marc R. Birtwistle, Antje‐Christine Walz. Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer. Clinical and Translational Science 2020; 13(2): 419 doi: 10.1111/cts.12727
|
| 34 |
Venkataswamy Sorna, Emily R. Theisen, Bret Stephens, Steven L. Warner, David J. Bearss, Hariprasad Vankayalapati, Sunil Sharma. High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. Journal of Medicinal Chemistry 2013; 56(23): 9496 doi: 10.1021/jm400870h
|
| 35 |
Jianwu Fang, Haiyan Ying, Ting Mao, Yanjia Fang, Yuan Lu, He Wang, Irene Zang, Zhaofu Wang, Ying Lin, Mengxi Zhao, Xiao Luo, Zongyao Wang, Yan Zhang, Chao Zhang, Wei Xiao, Yan Wang, Wei Tan, Zhui Chen, Chris Lu, Peter Atadja, En Li, Kehao Zhao, Jianfeng Liu, Justin Gu. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. Oncotarget 2017; 8(49): 85085 doi: 10.18632/oncotarget.18564
|
| 36 |
YUANXIA LI, XIAOLEI WAN, YE WEI, XIUWEN LIU, WENSHENG LAI, LIUPING ZHANG, JIE JIN, CHAOYANG WU, QIXIANG SHAO, GENBAO SHAO, QIONG LIN. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion. Oncology Reports 2016; 35(6): 3586 doi: 10.3892/or.2016.4729
|
| 37 |
Liming Wu, Lele Zhang, Shusen Zheng. Role of the long non-coding RNA HOTAIR in hepatocellular carcinoma. Oncology Letters 2017; 14(2): 1233 doi: 10.3892/ol.2017.6312
|
| 38 |
Shane O’Grady, Matthew W. Lawless. Epigenetic Cancer Therapy. 2015; : 269 doi: 10.1016/B978-0-12-800206-3.00012-4
|
| 39 |
Dominic C. Voon, Ruby Y. Huang, Rebecca A. Jackson, Jean P. Thiery. The EMT spectrum and therapeutic opportunities. Molecular Oncology 2017; 11(7): 878 doi: 10.1002/1878-0261.12082
|
| 40 |
Daniela Magliulo, Rosa Bernardi, Samantha Messina. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00255
|
| 41 |
Wenzhe Si, Yang Zhao, Jiansuo Zhou, Qiang Zhang, Yuan Zhang. The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101. Experimental Cell Research 2019; 379(1): 1 doi: 10.1016/j.yexcr.2019.03.017
|
| 42 |
So Young Kim, Supyong Hwang, Bo Ra Lee, Jung A. Hong, Young Hoon Sung, Inki Kim. Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells. Chemico-Biological Interactions 2022; 353: 109806 doi: 10.1016/j.cbi.2022.109806
|
| 43 |
Paola Vianello, Oronza A. Botrugno, Anna Cappa, Roberto Dal Zuffo, Paola Dessanti, Antonello Mai, Biagina Marrocco, Andrea Mattevi, Giuseppe Meroni, Saverio Minucci, Giulia Stazi, Florian Thaler, Paolo Trifiró, Sergio Valente, Manuela Villa, Mario Varasi, Ciro Mercurio. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry 2016; 59(4): 1501 doi: 10.1021/acs.jmedchem.5b01209
|
| 44 |
Yue-Yang Ji, Sen-Dong Lin, Yu-Jie Wang, Ming-Bo Su, Wei Zhang, Hendra Gunosewoyo, Fan Yang, Jia Li, Jie Tang, Yu-Bo Zhou, Li-Fang Yu. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. European Journal of Medicinal Chemistry 2017; 141: 101 doi: 10.1016/j.ejmech.2017.09.073
|
| 45 |
Qi Liu, Juan Xiong, Derong Xu, Nan Hao, Yujuan Zhang, Yi Sang, Zhigang Wang, Xiufen Zheng, Jeffrey Min, Hong Diao, Jacques Raphael, Saman Maleki Vareki, James Koropatnick, Weiping Min. TdIF1-LSD1 Axis Regulates Epithelial—Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer. International Journal of Molecular Sciences 2021; 23(1): 250 doi: 10.3390/ijms23010250
|
| 46 |
Shinji Takagi, Yoshinori Ishikawa, Akio Mizutani, Shinji Iwasaki, Satoru Matsumoto, Yusuke Kamada, Toshiyuki Nomura, Kazuhide Nakamura. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B. Cancer Research 2017; 77(17): 4652 doi: 10.1158/0008-5472.CAN-16-3502
|
| 47 |
Erin E. Grundy, Noor Diab, Katherine B. Chiappinelli. Transposable element regulation and expression in cancer. The FEBS Journal 2022; 289(5): 1160 doi: 10.1111/febs.15722
|
| 48 |
Simon J. Hogg, Paul A. Beavis, Mark A. Dawson, Ricky W. Johnstone. Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery 2020; 19(11): 776 doi: 10.1038/s41573-020-0077-5
|
| 49 |
Fernando Salvador Moreno, Renato Heidor, Igor P. Pogribny. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and Cancer 2016; 68(5): 719 doi: 10.1080/01635581.2016.1180410
|
| 50 |
Luca Sartori, Ciro Mercurio, Federica Amigoni, Anna Cappa, Giovanni Fagá, Raimondo Fattori, Elena Legnaghi, Giuseppe Ciossani, Andrea Mattevi, Giuseppe Meroni, Loris Moretti, Valentina Cecatiello, Sebastiano Pasqualato, Alessia Romussi, Florian Thaler, Paolo Trifiró, Manuela Villa, Stefania Vultaggio, Oronza A. Botrugno, Paola Dessanti, Saverio Minucci, Elisa Zagarrí, Daniele Carettoni, Lucia Iuzzolino, Mario Varasi, Paola Vianello. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. Journal of Medicinal Chemistry 2017; 60(5): 1673 doi: 10.1021/acs.jmedchem.6b01018
|
| 51 |
W Fiskus, S Sharma, B Shah, B P Portier, S G T Devaraj, K Liu, S P Iyer, D Bearss, K N Bhalla. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014; 28(11): 2155 doi: 10.1038/leu.2014.119
|
| 52 |
Nam Hoang, Xuan Zhang, Chunxiao Zhang, Van Vo, Feng Leng, Lovely Saxena, Feng Yin, Fei Lu, Guangrong Zheng, Pradip Bhowmik, Hui Zhang. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells. Bioorganic & Medicinal Chemistry 2018; 26(8): 1523 doi: 10.1016/j.bmc.2018.01.031
|
| 53 |
Chungang Liu, Limei Liu, Xuejiao Chen, Jiamin Cheng, Heng Zhang, Chengcheng Zhang, Juanjuan Shan, Junjie Shen, Cheng Qian. LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem–like Cells. Cancer Research 2018; 78(4): 938 doi: 10.1158/0008-5472.CAN-17-1236
|
| 54 |
Shuang Liu, Wenting Lu, Shouyun Li, Saisai Li, Jia Liu, Yuanyuan Xing, Shuzu Zhang, Joe Zhongxiang Zhou, Haiyan Xing, Yingxi Xu, Qing Rao, Chengjun Deng, Min Wang, Jianxiang Wang. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells. Oncotarget 2017; 8(19): 31901 doi: 10.18632/oncotarget.16650
|
| 55 |
Reiya Hayden, Markos Leggas. Novel Drug Treatments for Ewing Sarcoma. Current Molecular Biology Reports 2019; 5(4): 153 doi: 10.1007/s40610-019-00125-9
|
| 56 |
Keisuke Kosumi, Yoshifumi Baba, Akihisa Sakamoto, Takatsugu Ishimoto, Kazuto Harada, Kenichi Nakamura, Junji Kurashige, Yukiharu Hiyoshi, Masaaki Iwatsuki, Shiro Iwagami, Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida, Eiji Oki, Masayuki Watanabe, Shinjiro Hino, Mitsuyoshi Nakao, Hideo Baba. Lysine‐specific demethylase‐1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. International Journal of Cancer 2016; 138(2): 428 doi: 10.1002/ijc.29714
|
| 57 |
Tilak Khanal, Kwangmin Choi, Yuet-Kin Leung, Jiang Wang, Dasom Kim, Vinothini Janakiram, Sung-Gook Cho, Alvaro Puga, Shuk-Mei Ho, Kyounghyun Kim. Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11106-2
|
| 58 |
Emily R Theisen, Snehal Gajiwala, Jared Bearss, Venkataswamy Sorna, Sunil Sharma, Margit Janat-Amsbury. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-752
|
| 59 |
Tamara Maes, Cristina Mascaró, Alberto Ortega, Serena Lunardi, Filippo Ciceri, Tim C P Somervaille, Carlos Buesa. KDM1 Histone Lysine Demethylases as Targets for Treatments of Oncological and Neurodegenerative Disease. Epigenomics 2015; 7(4): 609 doi: 10.2217/epi.15.9
|
| 60 |
Xu-Dong Sun, Yi-Chao Zheng, Chao-Ya Ma, Jing Yang, Qi-Bing Gao, Ying Yan, Zhi-Zheng Wang, Wen Li, Wen Zhao, Hong-Min Liu, Lina Ding. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening. Journal of Biomolecular Structure and Dynamics 2019; 37(16): 4200 doi: 10.1080/07391102.2018.1538903
|
| 61 |
Yun-Duo Liu, Meng Dai, Shan-Shan Yang, Min Xiao, Fan-Ling Meng, Xiu-Wei Chen. Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma. International Journal of Gynecological Cancer 2015; 25(8): 1453 doi: 10.1097/IGC.0000000000000500
|
| 62 |
Zhaoliang Lu, Yanke Guo, Xiaoya Zhang, Jing Li, Leilei Li, Shuai Zhang, Changliang Shan. ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.01411
|
| 63 |
Qi-Sheng Ma, Yongfang Yao, Yi-Chao Zheng, Siqi Feng, Junbiao Chang, Bin Yu, Hong-Min Liu. Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors. European Journal of Medicinal Chemistry 2019; 162: 555 doi: 10.1016/j.ejmech.2018.11.035
|
| 64 |
Isamu Hoshino, Yasunori Akutsu, Kentaro Murakami, Naoki Akanuma, Yuka Isozaki, Tetsuro Maruyama, Takeshi Toyozumi, Yasunori Matsumoto, Hiroshi Suito, Masahiko Takahashi, Nobufumi Sekino, Aki Komatsu, Takayoshi Suzuki, Hisahiro Matsubara. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells. Annals of Surgical Oncology 2016; 23(1): 312 doi: 10.1245/s10434-015-4488-1
|
| 65 |
Meng Wang, Licheng Wang, Shusheng Wu, Dongsheng Zhou, Xianming Wang. Identification of Key Genes and Prognostic Value Analysis in Hepatocellular Carcinoma by Integrated Bioinformatics Analysis. International Journal of Genomics 2019; 2019: 1 doi: 10.1155/2019/3518378
|
| 66 |
Sophia Xiao Pfister, Alan Ashworth. Marked for death: targeting epigenetic changes in cancer. Nature Reviews Drug Discovery 2017; 16(4): 241 doi: 10.1038/nrd.2016.256
|